Rebecca Assaraf, Editor

About the Author Rebecca Assaraf, Editor


Glu Mobile Inc. (GLUU) Partners with WWE for the Making of New Wrestling Game: Another Tap Sports Baseball Phenomenon Ahead?

Just two days ago, Glu Mobile Inc. (NASDAQ:GLUU) announced it had entered into a multi-year …

Read more

Oracle Corporation (ORCL) Gets Price Target Boost on Excellent Earnings Results, Snap Inc (SNAP) Introduces Its Soon-To-Be “Big Hit”

Oracle Sees Strong Q4 Driven by Cloud Growth Oracle Corporation (NYSE:ORCL) reported excellent fiscal fourth-quarter results …

Read more

Piper Jaffray Remains Sidelined on Nike Inc (NKE) Ahead of Upcoming Earnings Report

With Nike Inc (NYSE:NKE) preparing to release fiscal fourth-quarter earnings on Thursday, June 29, Piper Jaffray …

Read more

Novadaq Technologies Inc. (NVDQ) Acquisition Could Spark a Bidding War

Yesterday, Novadaq Technologies Inc.(NASDAQ:NVDQ) shares skyrocketed 95% after the company announced it entered an ultimate agreement …

Read more

$100 Million Deal That Will Make Snap Inc Great Again?

Yesterday, Snap Inc (NYSE:SNAP) signed a “big” $100 million deal with Time Warner, agreeing to …

Read more

Pandora Media Inc (P) Redirects Attention to Fundamentals; Aegis Lowers Price Target

SiriusXM’s $480 million investment into Pandora Media Inc (NYSE:P) obviously ends any takeout speculation. As such, Aegis …

Read more

BMO Capital Remains Sidelined on Nokia Oyj (ADR) (NOK) Following Router Launch Event

Yesterday, BMO Capital analyst Tim Long attended Nokia Oyj (ADR) (NYSE:NOK)’s router launch event, where …

Read more

William Blair Shares Two Cents on Endo International plc (ENDP)

William Blair analyst Tim Lugo reiterates a Market Perform rating on shares of Endo International plc (NASDAQ:ENDP), following …

Read more

Chardan Capital Slashed Price Target on Regulus Therapeutics Inc (RGLS) Following Program Discontinuations

Yesterday, Regulus Therapeutics Inc (NASDAQ:RGLS) disclosed unpleasant updates regarding the company’s pipeline. The drug maker announced …

Read more

Coherus Biosciences Inc (CHRS) Hits ‘Speed Bump’ for CHS-1701; Maxim Remains Positive

Yesterday, Coherus Biosciences Inc (NASDAQ:CHRS) received a Complete Response Letter (CRL) from the FDA for …

Read more